期刊
NATURE REVIEWS ENDOCRINOLOGY
卷 13, 期 12, 页码 697-+出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrendo.2017.136
关键词
-
资金
- NIH [AG004875, AG048792, AR027065]
Romosozumab, a recently developed sclerostin inhibitor, stimulates bone formation and inhibits bone resorption, thereby markedly increasing bone mass and reducing fracture risk. But will a red flag regarding possible adverse cardiovascular events derail this promising new drug for osteoporosis?
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据